Amgen (AMGN) was Initiated by Bernstein to “Mkt Perform”. Bernstein advised their investors in a research report released on Jun 29, 2016.
On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.
Amgen closed down -1.87 points or -1.28% at $144.58 with 42,08,811 shares getting traded on Monday. Post opening the session at $146.16, the shares hit an intraday low of $143.82 and an intraday high of $147.07 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on May 5, 2016, Madhavan Balachandran (EVP, Operations) sold 30,000 shares at $154.12 per share price. According to the SEC, on May 3, 2016, Sean E Harper (EVP, Research & Development) sold 21,875 shares at $157.99 per share price. On May 3, 2016, David Baltimore (director) sold 3,312 shares at $157.21 per share price, according to the Form-4 filing with the securities and exchange commission.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.